Drug-eluting versus bare-metal stent for treatment of saphenous vein grafts: A meta-analysis

PLoS ONE

Volumn 5, Issue 6, 2010, Pages

  Meier, Pascal ^a,b   Brilakis, Emmanouil S ^c   Corti, Roberto ^d   Knapp, Guido ^e   Shishehbor, Mehdi H ^f   Gurm, Hitinder S ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^c Veterans Affairs North Texas Health Care System   (United States)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e TU DORTMUND UNIVERSITY   (Germany)

^f LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; RAPAMYCIN; DRUG; METAL;

ARTICLE; BARE METAL STENT; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DRUG ELUTING STENT; HEART REINFARCTION; HUMAN; META ANALYSIS; MORTALITY; RESTENOSIS; REVASCULARIZATION; RISK REDUCTION; SAPHENOUS VEIN GRAFT; STENT THROMBOSIS; SYSTEMATIC REVIEW; SAPHENOUS VEIN; STENT;

HUMANS; METALS; PHARMACEUTICAL PREPARATIONS; SAPHENOUS VEIN; STENTS;

EID: 77956202085     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011040     Document Type: Article

References (51)

1. Wilson CT, Fisher ES, Welch HG, Siewers AE, Lucas FL (2007) U.S. trends in CABG hospital volume: the effect of adding cardiac surgery programs. Health Aff (Millwood) 26: 162-168.
2. Brilakis ES, Wang TY, Rao SV, Banerjee S, Dai D, et al. (2010) Frequency and Predictors of Drug-Eluting Stent Use in Saphenous Vein Bypass Graft Percutaneous Coronary Interventions: A Report from the American College of Cardiology - National Cardiovascular Data Registry (abstract). presented at American College of Cardiology ACC scientific meetings 2010, March 14; Atlanta, Georgia.
3. Rodes-Cabau J, Bertrand OF, Larose E, Dery JP, Rinfret S, et al. (2009) Comparison of plaque sealing with paclitaxel-eluting stents versus medical therapy for the treatment of moderate nonsignificant saphenous vein graft lesions: the moderate vein graft lesion stenting with the taxus stent and intravascular ultrasound (VELETI) pilot trial. Circulation 120: 1978-1986.
4. Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, et al. (2009) Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 360: 213-224.
5. Safian RD (2002) Accelerated atherosclerosis in saphenous vein bypass grafts: a spectrum of diffuse plaque instability. Prog Cardiovasc Dis 44: 437-448.
6. Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, et al. (2006) Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial. J Am Coll Cardiol 48: 2423-2431.
7. Jeger RV, Schneiter S, Kaiser C, Bonetti PO, Brunner-La Rocca H, et al. (2009) Drug-eluting stents compared with bare metal stents improve late outcome after saphenous vein graft but not after large native vessel interventions. Cardiology 112: 49-55.
8. Brilakis ES, Lichtenwalter C, de Lemos JA, Roesle M, Obel O, et al. (2009) A randomized controlled trial of a paclitaxel-eluting stent versus a similar baremetal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial. J Am Coll Cardiol 53: 919-928.
9. Ribichini F, Pugno F, Ferrero V, Wijns W, Vacca G, et al. (2008) Long-term histological and immunohistochemical findings in human venous aorto-coronary bypass grafts. Clin Sci (Lond) 114: 211-220.
10. Brody WR, Kosek JC, Angell WW (1972) Changes in vein grafts following aortocoronary bypass induced by pressure and ischemia. J Thorac Cardiovasc Surg 64: 847-854.
11. Bulkley BH, Hutchins GM (1977) Accelerated ''atherosclerosis''. A morphologic study of 97 saphenous vein coronary artery bypass grafts. Circulation 55: 163-169.
12. Sankey S, Weissfeld L, Fine M, et al. (1996) An assessment of the use of the continuity correction for sparse data in metanalysis. Communications in Statistics: Simulation and Computation 25: 1031-1056.
13. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
14. Brouwers MC, Johnston ME, Charette ML, Hanna SE, Jadad AR, et al. (2005) Evaluating the role of quality assessment of primary studies in systematic reviews of cancer practice guidelines. BMC Med Res Methodol 5: 8.
15. Juni P, Witschi A, Bloch R, Egger M (1999) The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 282: 1054-1060.
16. Miller J (1978) The inverse of the Freeman-Tukey double arcsine transformation. The American Statistician 32.
17. R Development Core Team (2009) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, R project website (2010) http://www.R-project.org.
18. Hartung J, Knapp G, Sinha BK (2008) Statistical Meta-Analysis with Applications. Hoboken, NJ: Wiley-Interscience.
19. Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, et al. (2007) Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial. J Am Coll Cardiol 50: 261-267.
20. Shishehbor MH, Hawi R, Singh IM, Tuzcu EM, Bhatt DL, et al. (2009) Drugeluting versus bare-metal stents for treating saphenous vein grafts. Am Heart J 158: 637-643.
21. Chu WW, Rha SW, Kuchulakanti PK, Cheneau E, Torguson R, et al. (2006) Efficacy of sirolimus-eluting stents compared with bare metal stents for saphenous vein graft intervention. Am J Cardiol 97: 34-37.
22. Ge L, Iakovou I, Sangiorgi GM, Chieffo A, Melzi G (2005) Treatment of saphenous vein graft lesions with drug-eluting stents: immediate and midterm outcome. J Am Coll Cardiol 45: 989-994.
23. Lee MS, Shah AP, Aragon J, Jamali A, Dohad S, et al. (2005) Drug-eluting stenting is superior to bare metal stenting in saphenous vein grafts. Catheter Cardiovasc Interv 66: 507-511.
24. Hoffmann R, Pohl T, Koster R, Blindt R, Boeckstegers P, et al. (2007) Implantation of paclitaxel-eluting stents in saphenous vein grafts: clinical and angiographic follow-up results from a multicentre study. Heart 93: 331-334.
25. Wohrle J, Nusser T, Kestler HA, Kochs M, Hombach V (2007) Comparison of the slow-release polymer-based paclitaxel-eluting Taxus-Express stent with the bare-metal Express stent for saphenous vein graft interventions. Clin Res Cardiol 96: 70-76.
26. Ellis SG, Kandzari D, Kereiakes DJ, Pichard A, Huber K, et al. (2007) Utility of sirolimus-eluting Cypher stents to reduce 12-month target vessel revascularization in saphenous vein graft stenoses: results of a multicenter 350-patient casecontrol study. J Invasive Cardiol 19: 404-409.
27. Minutello RM, Bhagan S, Sharma A, Slotwiner AJ, Feldman DN, et al. (2007) Long-term clinical benefit of sirolimus-eluting stents compared to bare metal stents in the treatment of saphenous vein graft disease. J Interv Cardiol 20: 458-465.
28. Wilson BH, Humphrey AD, Cedarholm JC, Elliot CM, Haber RH, et al. (2007) Drug-eluting stents are no better than bare metal stents in vein grafts: results from the strategic transcatheter evaluation of new therapies (STEMT) group (abstract). American College of Cardiology ACC/i2 scientific meetings, March 25, 2007 Chicago, IL.
29. Voudris V, Kalianos C, Patsilinakos S, Manginas A, Pavlides G, et al. (2006) Effectiveness of drug-eluting stents in the treatment of bypass graft lesions (abstract). Eur Heart J 2006, 27(Abstract Suppl): 925.
30. Moore PA, Toney BM, Hermiller JB (2007) Off label use of drug-eluting stents: no advantage in saphenous vein grafts (abstract). Presented at Transcatheter Cardiovascular Therapeutics TCT meeting, Washington, DC, 2007.
31. Bansal D, Muppidi R, Singla S, Sukhija R, Zarich S, et al. (2008) Percutaneous intervention on the saphenous vein bypass grafts-long-term outcomes. Catheter Cardiovasc Interv 71: 58-61.
32. Gioia G, Benassi A, Mohendra R, Chowdhury K, Masood I, et al. (2008) Lack of clinical long-term benefit with the use of a drug eluting stent compared to use of a bare metal stent in saphenous vein grafts. Catheter Cardiovasc Interv 72: 13-20.
33. Assali A, Raz Y, Vaknin-Assa H, Ben-Dor I, Brosh D, et al. (2008) Beneficial 2- years results of drug-eluting stents in saphenous vein graft lesions. EuroIntervention 4: 108-114.
34. van Twisk PH, Daemen J, Kukreja N, van Domburg RT, Serruys PW (2008) Four-year safety and efficacy of the unrestricted use of sirolimus- and paclitaxeleluting stents in coronary artery bypass grafts. EuroIntervention 4: 311-317.
35. Vignali L, Saia F, Manari A, Santarelli A, Rubboli A, et al. (2008) Long-term outcomes with drug-eluting stents versus bare metal stents in the treatment of saphenous vein graft disease (results from the REgistro Regionale AngiopLastiche Emilia-Romagna registry). Am J Cardiol 101: 947-952.
36. May HT, Bair TL, Muhlestein JB, Horne BD, Li Q, et al. (2008) Use of Drug- Eluting Stents in Saphenous Vein Graft Lesions (abstract) Journal of the American College of Cardiology, March 11, 2008, Volume 51, Issue 10, Supplement A.
37. Okabe T, Lindsay J, Buch AN, Steinberg DH, Roy P, et al. (2008) Drug-eluting stents versus bare metal stents for narrowing in saphenous vein grafts. Am J Cardiol 102: 530-534.
38. Applegate RJ, Sacrinty M, Kutcher M, Santos R, Gandhi S, et al. (2008) Late outcomes of drug-eluting versus bare metal stents in saphenous vein grafts: Propensity score analysis. Catheter Cardiovasc Interv 72: 7-12.
39. Lozano I, Garcia-Camarero T, Carrillo P, Baz JA, de la Torre JM, et al. (2009) [Comparison of drug-eluting and bare metal stents in saphenous vein grafts. Immediate and long-term results]. Rev Esp Cardiol 62: 39-47.
40. Ramana RK, Ronan A, Cohoon K, Homan D, Sutherland J, et al. (2008) Longterm clinical outcomes of real-world experience using sirolimus-eluting stents in saphenous vein graft disease. Catheter Cardiovasc Interv 71: 886-893.
41. Kaplan S, Barlis P, Kiris A, Dimopoulos K, Celik S, et al. (2008) Immediate procedural and long-term clinical outcomes following drug-eluting stent implantation to ostial saphenous vein graft lesions. Acute Card Care 10: 88-92.
42. Jin-cheng G, Min X, Guo-zhong W, Chang-sheng M (2008) Late lumen loss of drug eluting stents versus bare mental stents for saphenous vein graft intervention. Journal of Clinical Rehabilitative Tissue Engineering Research 12: 6971-6975.
43. Latib A, Ferri L, Cosgrave J, Godino C, Romagnoli E, et al. (2008) A comparison of the long-term (2 year) safety and efficacy of drug-eluting and bare-metal stent implantation in saphenous vein grafts (abstract). Eur Heart J 29 (Supplement): 455-456.
44. Lichtenwalter C, de Lemos JA, Obel O, Abdel-karim AR, Roesle M, et al. (2010) Persistent Benefit From Paclitaxel-Eluting Stent Implantation in Saphenous Vein Grafts: Long-Term Results of the Stenting Of Saphenous Vein Grafts (SOS) Trial (abstract); presented at American College of Cardiology ACC scientific meetings 2010, March 14; Atlanta, Georgia.
45. Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Holper EM, et al. (2009) Clinical presentation and angiographic characteristics of saphenous vein graft failure after stenting: insights from the SOS (stenting of saphenous vein grafts) trial. JACC Cardiovasc Interv 2: 855-860.
46. Meier P, Gurm HS Drug-eluting versus bare metal stents-a one horse race? J Invasive Cardiol 22: 33-34.
47. Gualano SK, Gurm HS, Share D, Smith D, Aronow HD, et al. (2010) Temporal Trends in the Use of Drug-eluting Stents for Approved and Off-label Indications: A Longitudinal Analysis of a Large Multicenter Percutaneous Coronary Intervention Registry. Clin Cardiol 33: 111-116.
48. Meier P, Zbinden R, Togni M, Wenaweser P, Windecker S, et al. (2007) Coronary collateral function long after drug-eluting stent implantation. J Am Coll Cardiol 49: 15-20.
49. Brodie BR, Wilson H, Stuckey T, Nussbaum M, Laurent S, et al. (2009) Outcomes with drug-eluting versus bare-metal stents in saphenous vein graft intervention results from the STENT (strategic transcatheter evaluation of new therapies) group. JACC Cardiovasc Interv 2: 1105-1112.
50. Gurm HS, Boyden T, Welch KB (2008) Comparative safety and efficacy of a sirolimus-eluting versus paclitaxel-eluting stent: a meta-analysis. Am Heart J 155: 630-639.
51. Meier P, Knapp G, Tamhane U, Chaturvedi S, Gurm HS (2010) Short term and intermediate term comparison of endarterectomy versus stenting for carotid artery stenosis: systematic review and meta-analysis of randomised controlled clinical trials. BMJ 340: c467.